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One in every 1,000 newborn suffers from congenital
hearing impairment. More than 60% of the congenital cases
are caused by genetic factors. In most cases, hearing loss is
a multifactorial disorder caused by both genetic and
environmental factors. Molecular genetics of deafness has
experienced remarkable progress in the last decade. Genes
responsible for hereditary hearing impairment are being
mapped and cloned progressively. This review focuses on
non-syndromic hearing loss, since the gene involved in this
type of hearing loss have only recently begun to be
identified.
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INTRODUCTION
In developed countries, approximately 1/1,000
children have severe or profound hearing loss at birth or
during childhood, at pre-lingual stage. About 60% of the
cases have hereditary etiology, 30% of the cases are acquired,
and 10% are idiopathic. Non-syndromic forms are responsible
for 70% of the cases of hereditary etiology and syndromic
cases represent 30% of them. Among the forms of heritage,
autonomic recessive is the most frequent one (75%-85%),
followed by dominant heritage (12-13%) and X-linked or
mitochondrial, with 2-3% of the cases of non-syndromic
hearing loss.1,2
Syndromic or autosomal dominant hearing losses may
cause conductive, sensorineural or both losses. Conversely,
pre-lingual non-syndromic cases of autosomal recessive losses
are almost always sensorineural 1, 2. Syndromic abnormalities
caused by rubella, toxoplasmosis, cytomegalovirus, syphilis
or use of drugs in gestational period may cause hearing
disorders, which are congenital but not genetically-based,
such as other syndromic forms of hearing loss. Many of these
syndromes have already been described, and genes have
been mapped and cloned. 1
Some of the identified genes that cause syndromic
forms are also responsible for isolated forms of hearing loss.
There does not seem to be a direct correlation between this
type of mutations and the association with syndromic or
non-syndromic hearing loss. Moreover, analyses of
phenotypes together with mutations in some affected
families by Pendred or Usher syndrome, for example,
revealed that mutating gene of these syndromes may also
cause non-syndromic hearing loss. In such cases, it is highly
likely that modifying genes are contributing factors 3.
The purpose of the present study was to review some
genes described to present that, if mutating, cause the most
varied forms of non-syndromic hearing loss: autosomal
recessive, dominant, X-linked and mitochondrial. We selected
articles that were part of OMIM database using MedLine,
and the search mechanism used key words such as “deafness”
and “non-syndromic”. Selected articles were those that
provided the more recent information on genes involved
and their respective proteins, sites of expression in the
cochlea and audiological clinical picture.
LITERATURE REVIEW
Nomenclature of Non-syndromic Hearing Losses
Different chromosome sites of non-syndromic forms
of genetic deafness are named under the acronym DFN
(from English deafness) followed by letters A or B, meaning
autosomal dominant transmission (DFNA) and recessive
transmission (DFNB), respectively. When using DFN isolated,
it is X-linked deafness. After the letters, there is a whole
number, indicating the order of gene discovery.2
Hearing Physiology
To understand the consequences of gene mutations
that regulate the hearing process, we have to know about
normal cochlear physiology 4. After sound stimulus, sound
mechanical energy is converted into electrical signal
(mechanic-electrical transduction) in outer hair cells of the
cochlea. On the apical surface of these hair cells, there are
specialized microvillus - stereocilia - comprising corium with
actin and external recover of myosin, which oscillate in
response to sound, which is secondary to oval window stapes
movement, which moves the liquid that surrounds hair cells.
The deflection of neighboring stereocilia opens the
transduction channels in them, allowing inflow of potassium
from endolymph to both hair cells, causing depolarization
of cell membrane and activating calcium channels on the
basolateral surface of the membrane, which are sensitive to
voltage modifications. There is subsequent inflow of calcium
causing release of vesicles that contain neurotransmitters, in
the synaptic endings of 8th cranial nerve. Thus, after sound
stimulus, hair cells are hyperpolarized with high concentration
of intracellular potassium. So that new excitation is made
possible, potassium has to be removed. This movement of
potassium ions from hair cells to cochlear supporting cells,
going back to the endolymph, is made by intercellular and
specialized communications, the so-called communicating
junctions or gap junctions that exist between supporting
cells, fibrocytes of spiral ligament and spiral limbus.4
Molecular Genetics of Non-Syndromic Hearing Loss
Genetically-codified proteins with expression
on cochlear hair cells:
1) Non-conventional myosin proteins:
Non-conventional myosin proteins form a family that is
divided into 16 classes, found in most non-muscular cells 5.
They are smaller than muscle myosin and for this reason
they are called mini-myosin. These motor proteins form
filaments that move in actin filaments using energy
generated by ATP hydrolysis. In the cochlea, they have
been implied in the formation and movements of expansion
of cytoplasmatic membrane, synaptic vesicle movements
and transduction signals of outer and inner hair cells. 5
a) Myosin VIIA: it is expressed in inner ear outer hair cells
and in a great variety of epithelial cells that present
apical microvilosities, in addition to retina photoreceptor
cells. In the cochlea, the protein is present along the
stereocilia, close to the junction between hair cells and
supporting cells and present in the synaptic region,
Gene MYO7A, located in chromosome 11 (11q13.5),
has 49 exons that codify non-conventional myosin
protein VIIA (2215 amino acids).6
Mutations in the gene cause structural defects of the
protein and consequent affections in auditory function,
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responsible for non-syndromic firms of hearing loss,
one of profound recessive autosomal transmission –
DFNB2, comprising different grades of vestibular
dysfunction and variable age of onset, and another one
that is autosomal dominant – DFNA11, whose onset
takes place only after complete speech acquisition and
causes progressive hearing loss.6
When the mutations cause also retina cell abnormalities,
phenotypic picture is characterized as Usher syndrome.
The chromosomic site for one of the genetic types of
Usher syndrome – USH1B was also mapped in the
same region of chromosome 11, responsible for 75%
of the cases of USH type 1 7. Usher syndrome is the
more frequent cause of hearing loss associated with
blindness and vestibular pathology since childhood.
Studies on mutation of gene MYO7A that causes
DFNB2, DFNB11 and Usher1B were the first ones to
show that one single gene could determine both forms
of hearing loss, syndromic and non-syndromic 7.
b) Myosin XV: non-conventional protein (3,530 amino
acids) codified by gene MYO15 with at least 50 exons
and located on chromosome 17 (17p11.2). In the inner
ear, the expression of this gene seems to be restricted
to hair cells, on the cuticular plaque. Mutations of this
gene determine DFNB3.8
c) Myosin VI: gene MYO6 (32 exons), located at
chromosome 6 (6q13), codifies non-conventional
protein myosin VI (1262 amino acids), concentrated
on cuticular plaque of hair cells 1. Mutations determine
DFNA22 and DFNB37, characterized by progressive
hearing loss, post-lingual, which starts during childhood
(8 to 10 years to start symptoms, 6 to 8 years for onset
of audiometric affections), progressing to profound
level at the age of 50 anos.9
d) Myosin III: non-conventional protein recently described
in a Jewish family of Mosul, in Iraq, codified by gene
MYO3A (10p11.1).10 Mutations determine DFNB30,
characterized by bilateral progressive hearing loss that
affects primarily high frequencies, starting on the
second decade, and at age 50 years, it reaches severe
level in high and medium frequencies and moderate
level in low frequencies.10
2) Harmonin: gene site, if mutant, causes DFNB18, and was
mapped at chromosome 11 (11p15.1), at the same gene
location as USH1C (Usher Syndrome Type IC –
11p15.1).7,11 Gene USH1C (28 exons) codifies a protein
that contains domain PDZ, denominated harmonin. At the
cochlea, harmonin is restricted to hair cells, in which it is
present in the cellular body and stereocilia. In patients
with pre-lingual and severe DFNB18, mutation of gene
USH1 has been recently detected, located in an alternative
exon present in the transcription to the inner ear, but not
to the retina transcription 11. Functional characterization
of domain corresponding to harmonin protein provides
the understanding of the pathogenesis of DFNB18 and
USH1C syndrome.7
3) Villin: protein that belongs to the molecule that contains
PDZ domain; it acts as an organizer of submembranous
molecular complexes that control and coordinate
polymerization of actin for the growth of membrane in
stereocilia of inner and outer hair cells. Gene villin (9q32-
q34), with 12 exons, codifies protein of the same name,
with 465 amino acids and if mutant they are responsible
for pre-lingual profound DFNB31. Protein villin is similar
to protein harmonin because it shares 95% of its three
PDZ domains.12
4) Cadherin-23: it belongs to the family of transmembrane
proteins, dependent on Ca2+ ions, with over 20 different
members, making part of a molecular structure of
intercellular adhesion junctions or zones of adhesion
(zonnula adherens). Chromosome sites for DFNB12
(10q21-q22)13 and Usher syndrome Type I (USH1D –
10q)7 were mapped in chromosome 10. Gene CDH23,
with 69 exons codifies protein cadherin-23 (3354 amino
acids) expressed in both cochlear hair cells, promoting
strong adhesion between each of their types, maintaining
polarization of plasma membrane depending on occlusion
junctions (claudin-14 protein) and cytoskeleton. Mutations
of gene CDH23 were detected in families with DFNB12,
which presented pre-lingual profound hearing loss 13.
Conversely, only deletions or displacements were found
in patients with USH1D.7 Therefore, the type of mutation
can have a crucial role in phenotypic expression.
5) Diaphanus-1: it belongs to family of proteins related to
formins, involved in cell polarization and cytokinesis. Gene
DIAPH1 or HDIA1 (26 exons), located at chromosome 5
(5q31), codifies protein diaphanous-1 (1252 amino acids),14
homologous to protein diaphanous of Drosophila. At the
cochlea, the protein is found in hair cells and external
supporting cells, but in small concentrations. Gene
mutations affect the cytoskeleton of actin in outer hair cells
and cause DFNA1, described in a family in Costa Rica, in
which they located the first affected ancestral named
Monge.14 It is characterized by progressive hearing loss
that at first affects low frequencies (Konigsmark syndrome,
by identification of three families with hearing loss and this
audiological pattern). At the age of 40 years, approximately,
hearing loss reaches severe level in all frequencies.14
6) KCNQ4: gene KCNQ4, with 14 exons, mapped in
chromosome 1 (1p34), codifies a protein subunit of family
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KCNQ of potassium channels, protein KCNQ4 (695 amino
acids). In the cochlea, channels KCNQ4 are expressed
not only in outer hair cells, but also in inner hair cells,
whose main function is to promote the outflow of
potassium from the cells to supporting cells.15 Mutations
of this gene were identified in families affected by
progressive hearing loss – DFNA2, starting at adolescence
or at the age of 20 years, and preferably involving high
frequencies, becoming profound within 10 years.15
7) Otoferlin: gene OTOF, with 48 exons, codified protein
otoferlin (1977 amino acids) located at chromosome 2
(2p22-p23), whose mutation determines DFNB9,
characterized by pre-lingual profound hearing loss
involving all frequencies.16 Protein otoferlin is expressed
in inner hair cells and it is involved in the fusion, triggered
by calcium, of synaptic vesicles with the plasma
membrane, releasing glutamate neurotransmitter to the
afferent innervation system to take the sound message
codified by inner hair cells in the form of electrical impulses
to the central auditory areas.16
8) POU4F3: A deletion of only 8 base pairs was the mutation
found in gene POU4F3 (2 exons), located in chromosome
5 (5q31), determining DFNA15, starting between 18 and
30 years, progressive, and which reaches moderate to
severe level at the age of 50, approximetaly.17 Gene
POU4F3 codifies transcription factor of the same name
(338 amino acids), belonging to the family of proteins of
domain POU. In both hair cells in the cochlea, gene
POU4F3 seems to express the migration of the same
layers of supporting cells for the hair cell layer of the
lumen in addition to their maturation and survival.17
Proteins genetically codified with expression
on cochlear non-sensorial cells:
1) Protein connexin:
Protein connexin is the structural component of
intercellular gap junctions, which are responsible for flow
of potassium of supporting cells for fibrocytes of spiral
ligament and spiral limbus back to endorphin, after it has
been out from the hair cells.
a) Connexin 26: in 1997, gene connexin 26 (13q11-12)
was discovered, whose mutations caused DFNA3 and
DFNB1.18 It has taken to the assumption that gene
Cx26 or GJB2, with only one exon, codifies protein
connexin 26 (226 amino acids), which can be
responsible for both forms of hearing loss. Hearing loss
is characterized by being pre-lingual, non-progressive,
profound, with high threshold values in all frequencies.18
b) Connexin 31: it has not been determined yet if protein
connexin 31 (270 amino acids) is present in all gap
junctions of the inner ear. The site of Cx31 or GJB3, in
chromosome 1 (1p34) is the same for gene KCNQ4,
expressed in both hair cells, and if mutant, it causes
DFNA2.19 Owing to that, mutations of gene Cx31 also
cause dominant hearing loss, but even with the
expression in different site of gene KCNQ4, both
received the same name – DFNA2.
c) Connexin 30: the gene that codifies connexin 30 (261
amino acids) is located in chromosome 13 (13q12)20
and if mutant it causes DFNA3 and DFNB1 (both forms
also caused by Cx26). If no mutation is found in gene
Cx26 or in heterozygote patients for 35delG, mutations
of gene Cx30, by its close relation (about 76% of identical
amino acids) and proximity of its chromosomic location
to gene Cx26, they may be considered responsible for
hearing loss, named similarly to Cx26. This fact is
explained, in addition to proximity, by the fact that Cx26
and Cx30 may form heterotopic channels of connexons
and they have the same cellular distribution in the
cochlea. Therefore, pathophysiological hypotheses
concerning hearing loss associated with Cx26 and Cx30
are similar.20
2) Pendrin: Protein pendrin (780 amino acids) is codified by
gene PDS (21 exons), located at chromosome 7. Mutations
in this gene are responsible both by Pendred Syndrome
(7q21-34) and DFNB4 (gene SLC26A4 – 7q31).21 DFNB4
is characterized by progressive hearing loss and widening
of vestibular aqueduct, without thyroid affection. In the
mature cochlea, protein pendrin is expressed in prominent
spiral cells and cells adjacent to external spiral sulcus.21
3) Claudin-14: gene CLDN14, located in chromosome 21
(21q22), codified protein claudin (239 amino acids), one
of the components of gap junctions or tight junctions.22
Occlusion or gap junctions limit the passive diffusion of
ions and small molecules through intercellular space, in
addition to maintaining cellular polarity together with
cytoskeleton and adhesion junctions (cadherin-23 protein).
In the cochlea, the gene is expressed in hair cells and
supporting cells. Mutations of this gene are responsible
for DFNB29.22
4) Cocline: protein cocline (550 amino acids) is codified by
COCH (11 exons), located in chromosome 14 (14q12-
q13). In the cochlea, the gene is expressed in spiral ganglion
and extracellular matrix especially spiral limbus, spiral
ligament and bone spiral lamina.23 Mutations are responsible
for DFNA9, which starts between the ages of 20 and 30
years, approximately. Initially, it is profound in high
frequencies with variable progression to anacusis at the
age of 40-50 years. The spectrum of vestibular involvement
varies from absence of symptoms to presence of vertigo
and vestibular hypofunction. Mutations of gene COCH may
be one of the genetic factors that contribute to symptoms
of Mèniére Disease, and this hypothesis should be
220
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 71 (2) PART 1 MARCH/APRIL 2005
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
considered in patients with symptoms of the disease.23
Histopathological analyses of temporal bone in patients
with DFNA9 showed deposits of mucopolysaccharides in
cochlear and vestibular nerve channels. These findings
suggest that deposits may take to degeneration of inner
ear neural fibers, causing hearing loss.1
5) EYA4: gene EYA4 (21 exons), a member of family EYA
homologous to Drosophila eyes absent (regulator of ocular
development of Drosophila), was mapped in chromosome
6 (6q22.3-23.3) that codifies protein EYA4 (639 amino
acids).24 Genes EYA are expressed in different tissues at
the beginning of embryogenesis, and even though each
gene EYA has one single pattern of expression, there is
major overlapping, that is, EYA1 and EYA4 are both
expressed in the optic vesicle and in its derivates.
Differently from the phenotype resulting from mutations
in gene EYA1 (Brachio-Oto-Renal Syndrome), no
congenital anomaly is part of phenotype of DFNA10,
characterized by progressive hearing loss whose onset is
from 2nd to 5th decades, progressing from severe to
profound loss. Losses start in medium frequencies and
eventually involve low and high frequencies. 24
6) POU3F4: Gene POU3F4 (1 exon), mapped in chromosome
X (Xq21.1) is responsible for transcription regulating
elements.25 Expression of gene POU3F4 in the
development of the inner ear is restricted to the
mesenchyma. Transcription starts when mesenchyma is
condensed to originate the optical capsule and protein
POU3F4 (361 amino acids), remaining in the nuclei of
mesenchymal cells. They then migrate to cavitary regions
of temporal bone to form scala vestibularis, scale tympany
and internal acoustic canal. In adult cochlea, the gene is
expressed in the fibrocytes of spiral ligament. Mutations
in these genes cause DFN3, the first non-syndrome form
that is X-linked. It has a unique phenotype because
affected patients present conductive hearing loss that is
probably caused by fixation of stapes, together with
progressive profound hearing loss.25
Genetically codified proteins with expression
on tectorial membrane:
1) Collagen XI (alpha2 chain): Collagen XI protein, codified
by gene COL11A2 (62 exons) located in chromosome 6,
is one of the components of tectorial membrane.26 It is
an acellular membrane comprising many different types
of collagen (II, V, IX, XI), non-collagen proteins and
proteoglicans, and it is involved in deflection of ciliary
bundle of cochlear outer hair cells, immediately after sound
stimulus.5 Mutations of gene COL11A2 cause both DFNA13
(6p21), such as Stickler syndrome Type 2 (STL2 – 6p21.3,
progressive myopia, early vitreo-retina and articular
degeneration, facial hypoplasia, deafness). DFNA13 is
characterized by post-lingual progressive loss starting from
the 2nd and 4th decades of life and there are some rare
patients with vestibular disorders.26
2) Alpha-tectorine: many different types of cells synthesize
alpha-tectorine protein during development of the inner
ear. Due to sequence of DNA in TECTA gene, it is assumed
that tectorine protein is synthesized from a precursor
adjacent to plasma membrane, via glycosil-phosphatidyn-
inositol, released from the membrane by proteolytic
cleavage of precursor. Gene TECTA (23 exons), located
in chromosome 11, codifies alpha-tectorine protein (2155
amino acids) and it is one of the components of tectorial
membrane.27 Mutations in gene cause two forms of
autosomal dominant hearing loss (DFNA8 and DFNA12 –
11q22-24, both pre-lingual and they may be progressive
and non-progressive) and an autosomal recessive form
(DFNB21 – 11q, pre-lingual, severe to profound).27
Phenotypic expression may range depending on the
occurrence of impaired alleles, because s Swiss family
was identified as possibly being a digenic penetrance of
hearing loss, involving location of DFNA12, in chromosome
11, and location DFNA2 in chromosome 1.28
Forms of hearing loss caused by mitochondrial
DNA affections:
Diseases related to mitochondrial DNA are transmitted
to both genders, only by the mother, and they may be
syndromic or non-syndromic. Mitochondral DNA codifies 13
RNA messenger (RNA-m), 2 RNA ribosomic (RNA-r) and 22
RNA-transporters (RNA-t).
Mutation 1555A->G was detected in mitochondrial
gene 12S rRNA in patients with family hearing loss and also
in isolated cases of hearing loss induced by the use of
aminoglycoside antibiotics.29 This mutation takes susceptible
subjects to hearing loss after treatment with aminoglycosides
in concentrations that would not normally affect hearing.29
To present, other described non-syndromic
mitochondrial mutations that cause hearing loss followed or
not by other affections are located in gene RNA-transporter
– gene tRNA Ser (UCN): 7445A->G= keratoderm
palmoplantar; 7472insC= neurological dysfunction – ataxia,
dysarthria and myoclonus; 7510T->C and 7511T->C= only
hearing loss. Syndromic mitochondrial mutations can also be
located in RNA-t, causing hearing loss associated with
neuromuscular syndrome or diabetes mellitus. Recent studies
suggested that mitochondrial mutations, such as deletions
del4977 pb, del4834 pb and del3867 pb may be responsible
for family cases of presbyacusis .1,3
Otosclerosis
Hearing loss caused by clinical otosclerosis has
prevalence of 0.2 to 1% among Caucasian adults. The mean
age of onset is 3rd decade and 90% of affected patients are
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below the age of 50 years at the time of diagnosis.
Conductive hearing loss is developed when the focus invades
stapedial-vestibular articulation, on the oval window,
interfering with free movement of stapes. Profound
sensorineural hearing loss, reaching all frequencies, may also
be present, characterizing cochlear otosclerosis, in about 10%
of affected subejcts.1,3 Location of OTSC1, OTSC2 and
OTSC3, respectively, in chromosomes 15 (15q26.1-qter), 7
(7q34-q36) and 6 (6p21.3-22.3) were identified in families
with autosomal dominant transmission for otosclerosis.
However, in most cases, etiology remains unknown.30
DISCUSSION
The fact that one same mutation leads to different
clinical presentations may be the indication that the
knowledge of molecular genetics has not reached the details
of auditory dynamics yet, as well as the myriad of neurological
abnormalities involved. However, it seems to move towards
that. New mutations are described, new genes are cloned
and mapped, and there are about 34 genes already identified
to form recessive autosomal non-syndromic forms, 40 genes
for dominant autosomal forms, 8 for X-linked forms, and 2
genes for mitochondrial heritage.1,2
Despite the significant advances in understanding
molecular basis of hearing loss, precise identification of
genetic cause still presents some difficulties, owing to
phenotypical variation. First we have to rule out non-genetic
causes, then syndromic causes, and then look for non-
syndromic causes.
Most non-syndromic recessive autosomal forms cause
pre-lingual loss that is severe to profound and not associated
with radiological findings. Exception to this rule are DFNB2
(MYO7A)6, DFNB8/10 (TMPRSS3) and DFNB16 (STRC)1,3
in which age at onset may occur in later phases of childhood;
DFNB4 (SLC26A4)21 in which there may be dilation of
vestibular aqueduct and endolymphatic sac, and DFNA9
(COCH)23 that may be associated with degeneration of
cochlear nerve fibers by deposits of mucopolysaccharides.
Not very frequent phenotypes in autosomal dominant forms
of hearing loss include low frequency hearing loss in DFNA1
(HDIA1) and DFNA6/14/38 (WFS1),1,3 medium frequency
loss in DFNA8/12 (TECTA)27 and DFNA13 (COL11A2)26 and
vestibular signs and symptoms in DFNA9 (COCH)23 and
sometimes in DFNA11 (MYO7A).6 Owing to the great variety
of genes involved, and in view of costs, assessment should
be the most specific possible, maybe based on clinical
picture. Expectations concerning results and conclusion in
relation to them should be very careful.
Otorhinolaryngologists, pediatricians and geneticists
should be aware of this phenotypical variety and especially
that DFNB1 is the most frequent form of non-syndromic
recessive autosomal hearing loss; molecular investigation
should be made in such cases, reducing the costs of
complementary tests normally requested for the investigation
of patients with hearing loss.
Facility and benefits of genetic tracking, especially for
mutations that cause DFNB1, should make it an important public
health issue so that determinations of early diagnosis of hearing
loss can be properly established. Molecular tests can not help
all children with hearing loss and it is not reasonable to wait for
these tests to replace already existing screening programs.
Whether or not screening programs with acoustic otoemissions
and brainstem evoked audiometry should include molecular
tests for DFNB1 is another different issue.
Genetic counseling of families whose parents have
normal hearing and one single hearing child has been very
difficult owing to nonexistence of genetic tests to identify
specific mutations, especially in developing countries. In
most cases, considering the important role of environmental
causes of pre-lingual hearing loss, it is difficult to recognize
whether hearing loss is of genetic origin. It is essential to
inform healthcare professionals, the general population, and
the hearing impaired population about genetic advances,
and to train professionals on genetic counseling.
Genetic tests for hearing loss are a reality because
they have changed the assessment pattern of patients with
hearing impairment and should be used by physicians for
diagnostic purposes. In the next years, there will certainly
be an expansion in the role of these tests and counseling
will not be limited to reproductive results. Even though tests
may be confusing for medical professionals that are not used
to them, in daily practice, they are an important part of
medical care. New findings and technologies will expand
and enhance complexity of these tests and it will be on
Otorhinolaryngologists and Pediatricians to get familiar with
recent discoveries and include them in their investigation
protocols - the genetic tests.
Reaction to sounds is the first sign that a child has his
auditory capacity preserved. Owing to delay in speech
acquisition, absence of reaction to sounds or other disorders,
parents are the first ones to suspect of hearing loss. The
delay between suspicion and diagnosis reduces significantly
the possibilities of rehabilitation, because if intervention does
not take place early, it will cause communication deficits
that have significant morbidity, which can be manifested by
paucity of social activities and professional opportunity
losses. Conversely, it is surprising that some parents and
even some professionals hesitate to accept hearing loss,
considering it as unimportant, translating lack of knowledge
about the importance of auditory function for the
development of conceptual processes that support human’s
reasoning and speech.
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